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This population-based anal-
ysis compared patients with
nodular lymphocyte-
predominant Hodgkin lym-
phoma (NLPHL) to those
with classical Hodgkin lym-
phoma (CHL). We found that
controlling for earlier stage
and more favorable present-
ing characteristics resulted in
a better prognosis for pa-
tients with NLPHL than for
CHL patients. We also found
an association between radi-
ation therapy and improved
survival in NLPHL patients,
whereas we showed a decline
in the use of radiation ther-
apy over time among
NLPHL patients.Reprint requests to: Joachim Yahalom, MD
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http://dx.doi.org/10.1016/j.ijrobp.2015.02.012Purpose: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is rare,
comprising approximately 5% of all Hodgkin lymphoma (HL) cases. Patients with
NLPHL tend to have better prognoses than those with classical HL (CHL). Our goal
was to assess differences in survival between NLPHL and CHL patients, controlling
for differences in patient and disease characteristics.
Methods and Materials: Using data from the population-based Surveillance, Epidemi-
ology and End Results (SEER) cancer registry program, we identified patients diag-
nosed with pathologically confirmed HL between 1988 and 2010.
Results: We identified 1,162 patients with NLPHL and 29,083 patients with CHL.
With a median follow-up of 7 years, 5- and 10-year overall survival (OS) rates were
91% and 83% for NLPHL, respectively, and 81% and 74% for CHL, respectively. Af-
ter adjusting for all available characteristics, NLPHL (vs CHL) was associated with
higher OS (hazard ratio [HR]: 0.62, P<.01) and disease-specific survival (DSS; HR:
0.48, P<.01). The male predominance of NLPHL, compared to CHL, as well as the
more favorable prognostic features in NLPHL patients are most pronounced in
NLPHL patients <20 years old. Among all NLPHL patients, younger patients were
less likely to receive radiation, and radiation use has declined by 40% for all patients
from 1988 to 2010. Receipt of radiation was associated with better OS (HR: 0.64,
PZ.03) and DSS (HR: 0.45, PZ.01) in NLPHL patients after controlling for available
baseline characteristics. Other factors associated with OS and DSS in NLPHL patients
are younger age and early stage.
Conclusions: Our results in a large population dataset demonstrated that NLPHL pa-
tients have improved prognosis compared to CHL patients, even after accounting for, Department of Radiation
Center, New York, NY
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Volume 92  Number 1  2015 A SEER analysis of NLPHL 77stage and baseline characteristics. Use of radiation is declining among NLPHL patients
despite an association in this series between radiation and better DSS and OS. Unique
treatment strategies for NLPHL are warranted in both early and advanced stage disease.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
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Nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL) is a rare histological subtype, comprising
approximately 5% of all HL cases (1). The clinical charac-
teristics, treatment approach, and outcomes of patients with
NLPHL differ from those of classic HL (CHL) (1-4).
NLPHL patients tend to present at an earlier stage and have
an improved prognosis compared to patients with CHL
(2, 5). A study from the German Hodgkin Study Group
(GHSG) comparing 394 patients with NLPHL to 7,904 pa-
tients with CHL found that patients with NLPHL had lower
rates of adverse prognostic features such as advanced stage
at presentation, B-symptoms, involvement of 3 nodal
areas, elevated erythrocyte sedimentation rate (ESR),
elevated lactate dehydrogenase level, mediastinal bulky
tumor or extranodal involvement. This study found im-
proved overall survival (OS) and freedom from treatment
failure (FFTF) in NLPHL patients compared with CHL
patients (2).
Whether this survival advantage of NLPHL patients
persists after controlling for the more favorable presenta-
tion and earlier stage of NLPHL patients is not known. In
the GHSG data, there were no differences in FFTF after
controlling for early favorable, early unfavorable, and
advanced stage at presentation (2). Similarly, a comparison
of patients with stage IA or IIA NLPHL and those with
CHL without mediastinal involvement found no differences
in OS between the 2 groups and, in contrast to the GHSG
data, similar presenting characteristics between the 2
groups (6). A matched-pairs analysis from the British
Columbia Cancer Agency of advanced stage patients with
NLPHL and CHL patients treated with chemotherapy
revealed shorter time to progression among NLPHL
patients compared to CHL patients, although OS and FFTF
were similar between the 2 groups (7).
Among patients with NLPHL alone, there is a paucity of
data regarding prognostic factors as much of the data are
extrapolated from studies that include all HL patients, most
of whom have CHL. Furthermore, although differences
between adult and pediatric patients with HL have been
described (8), it is unclear which of these differences ap-
plies specifically to NLPHL patients. Finally, there is evi-
dence that the use of radiation is declining among patients
with CHL and it is unclear if this trend applies to NLPHL
patients as well (9).
Our objective was to examine differences between pa-
tients with NLPHL and CHL in a large population-based
cohort. Specifically, we examined differences between the 2groups in their demographic and disease characteristics and
survival. We also studied NLPHL patients alone to evaluate
trends in the use of radiation, and associations between
receipt of radiation and demographic and disease
characteristics.
Methods and Materials
Data
We analyzed data from the National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER) cancer
registry program, a consortium of population-based cancer
registries.We identified cases ofHLdiagnosed between 1988
and 2000 from 13 registries and cases diagnosed between
2000 and 2010 from 18 registries covering 14% and 28% of
the US population in each time period, respectively, reflect-
ing an expansion of the SEER program after 2000. SEER
registries collect information regarding site and extent of
disease, first course of cancer-directed therapy, and socio-
demographic characteristics, with active follow-up for date
and cause of death for all incident cancers. The SEERdata are
publicly available, and the study was considered exempt
from informed consent requirements.
Study cohort
We identified patients with a pathologically confirmed
diagnosis of HL. We excluded patients with a diagnosis of
Hodgkin sarcoma or Hodgkin granuloma. We also excluded
patients with a previous cancer diagnosis in SEER and
those whose condition was diagnosed only at the time of
death. We excluded patients who were missing information
about stage or radiation.
Outcomes and covariates
The outcomes were OS and disease-specific survival (DSS).
HL-specific deaths were obtained from the SEER Cause-
Specific Death Classification, where deaths attributed to the
cancer of interest are treated as events, and deaths from
other causes are censored. Death records were complete
through December 2011.
The predictor of interest was type of HL, classified as
CHL and NLPHL. Demographic covariates included patient
age at diagnosis, sex, race and geographic region. Age at
diagnosis was classified as under age 20, 20-45, and over 45.
Disease characteristics included histologic subtype, stage,
Table 1 Characteristics of nodular lymphocyte-predominant
versus those of classical Hodgkin lymphoma patients
Characteristic
NLPHL Classic HL
P
nZ1162 nZ29,083
n % n %
Median age at
diagnosis (IQR)
38 (25-53) 35 (24-51) .0562*
Age at diagnosis
<20 186 16% 3936 14% <.0001
20-45 441 38% 9308 32%
>45 535 46% 15,839 54%
Sex
Male 806 69% 15,723 54% <.0001
Female 356 31% 13,360 46%
Race
White 853 73% 24,682 85% <.0001
Black 258 22% 3119 11%
Other 51 4% 1282 4%
Geographic region
Midwest 190 16% 4132 14% .02
Northeast 171 15% 4984 17%
South 213 18% 4832 17%
West 588 51% 15,135 52%
Urban/rural
Metropolitan 1056 91% 25,931 89% NS
Nonmetropolitan 106 9% 3152 11%
Income quartile
Lowest quartile 245 21% 7370 25% <.0001
Second quartile 312 27% 8113 28%
Third quartile 253 22% 6458 22%
Fourth quartile 352 30% 7142 25%
Stage
I 578 50% 5735 20% <.0001
II 303 26% 12,079 42%
III 204 18% 5921 20%
IV 77 7% 5348 18%
Extranodal extension
Yes 129 11% 7011 24% <.0001
No 1033 89% 22,072 76%
B symptoms
Absent 765 66% 12,128 42% <.0001
Present 131 11% 10,815 37%
Unknown 266 23% 6140 21%
Radiation
Received 564 49% 11,585 40% <.0001
Did not receive 598 51% 17,498 60%
Diagnosis year
1988-1994 113 10% 5064 17% <.0001
1995-2010 1049 90% 24,019 83%
Abbreviations: IQR Z interquartile range; NLPHL Z nodular
lymphocyte-predominant Hodgkin lymphoma; NS Z not significant.
* Kruskal-Wallis test was used for differences in medians.
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and diagnosis year. SEER staging is based on the Ann Arbor
Staging system and was classified as early (stages I and II)
and late (stages III and IV) stage. Diagnosis years were
grouped as 1988 to 1994 and 1995 to 2010.
Statistical analysis
Unadjusted associations between Hodgkin type (CHL vs
NLPHL) and demographic and disease characteristics were
assessed using c2 statistics. Kaplan-Meier methods were
used to estimate survival functions, and the log-rank test
was used to compare the resulting unadjusted survival
curves. Cox proportional-hazards regression was used to
estimate the impact of type of HL (CHL vs NLPHL) on
overall and HL-specific survival, controlling for de-
mographic and disease characteristics. All variables were
entered into the multivariate model. Hazard ratios, 95%
confidence intervals, and 2-sided P values were estimated
for each covariate. Competing-risks regression models were
also used to assess the impact of characteristics on out-
comes, with observations censored at the end of follow-up
and death from other causes treated as competing events.
We performed stratified analyses to assess whether the
relationship between types of HL and death varied by stage
at diagnosis.
Similar analyses were also performed in the subset of
patients with a diagnosis of NLPHL to assess the impact of
demographic and disease characteristics on the risk of
overall and HL-specific death. In addition, we assessed
unadjusted associations of age at diagnosis with de-
mographic and disease characteristics in this subset. We
estimated trends in radiation use over time and use of ra-
diation by age and stage.
Analysis was performed using SAS version 9.2 software
(SAS Institute, Cary, NC) and R software (R Foundation for
Statistical Computing, Vienna, Austria).
Results
We identified 1,162 patients with NLPHL and 29,083
patients with CHL. Median age at diagnosis of NLPHL
and CHL was 38 and 35 years of age, respectively.
NLPHL patients were more likely to be male (69% vs
54%, respectively, P<.01) and black (22% vs 11%,
respectively, P<.01) (Table 1). NLPHL patients were more
likely to present with stage I disease (50% vs 20%,
respectively, P<.01) and less likely to have B symptoms
(11% vs 37%, respectively, P<.01) or extranodal exten-
sion (11% vs 24%, respectively, P<.01). NLPHL patients
were more likely to have received radiation therapy (RT;
49% vs 40%, P<.01). Among early-stage patients, 59% of
NLPHL versus 52% of CHL patients received radiation.
NLPHL patients were more prevalent among the highest
income quartile whereas CHL patients were more preva-
lent in the lowest income quartile.With a median follow-up of 6.9 years, rates of 5-, 10-,
and 15-year OS were 91%, 83%, and 73%, respectively,
for NLPHL patients and 81%, 74%, and 69%, respec-
tively, for CHL patients (P<.01) (Fig. 1). DSS rates at 5,
10, and 15 years were 95%, 93%, and 88% for NLPHL
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Fig. 1. (a) Overall survival for early stage patients by subtype. (b) Overall survival for advanced stage patients by subtype.
(c) Disease-specific survival for early stage patients by subtype. (d) Disease-specific survival for advanced stage patients by
subtype. NLP Z nodular lymphocyte-predominant Hodgkin lymphoma.
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(P<.01). This survival advantage among NLPHL patients
was present among both early stage patients (P<.01) and
advanced stage patients (P<.01). Similarly, DSS was
better in NLPHL patients with early (P<.01) or late stage
(P<.01) disease. In multivariate analysis (MVA) for OS
and DSS, NLPHL was associated with better OS (HR:
0.62, 95% CI 0.53-0.73, P<.01) and DSS (HR: 0.48, 95%
CI 0.38-0.62, P<.01).
The male predominance in NLPHL (vs CHL) was most
pronounced among NLPHL patients <20 years old (78%)
with the male predominance decreasing with increasing
age. The more favorable baseline characteristics among
NLPHL (vs CHL patients) such as lower incidence of B
symptoms and extranodal disease were also most pro-
nounced in the younger NLPHL patients (Table 2). As
shown in Figure 2, radiation use differed by age among
early stage patients, with younger patients least likely to
receive radiation (38%) compared to patients 20 to 45 years
of age (59%) and patients >45 years of age (66%). Use of
radiation in NLPHL declined from 70% of NLPHL patients
in 1988 to 1990 to 42% in 2006 to 2010 (Fig. 3),representing a 40% decline over this time period. This trend
was observed in both early-stage patients and advanced-
stage patients, with a 31% relative decrease among early
stage patients and a 61% relative decrease among advanced
stage patients over the study period.
In NLPHL patients, younger age at diagnosis, early
stage, and receipt of radiation were all associated with
better OS and DSS, controlling for other disease and de-
mographic characteristics (Table 3 and see Supplementary
Table E1; available online at www.redjournal.com).Discussion
Much of the data for prognosis, outcomes, and treatment
strategies in NLPHL were derived from series of HL, of
which NLPHL patients comprise a small percentage of the
total number of studied patients. When NLPHL is exam-
ined in comparison to CHL, conflicting data emerges. The
GHSG analysis of greater than 8,000 patients demonstrated
improved prognosis in NLPHL compared to CHL patients
(2). Yet there was no difference in FFTF between NLPHL
Table 2 Nodular lymphocyte-predominant Hodgkin lymphoma patient characteristics by age at diagnosis
Characteristic
Age at diagnosis
P
<20 (nZ186) 20-45 (nZ535) >45 (nZ441)
n % n % n %
Sex
Male 146 78% 382 71% 278 63% .001
Female 40 22% 153 29% 163 37%
Race
White 147 79% 376 70% 330 75% .04
Black 28 15% 137 26% 93 21%
Other 11 6% 22 4% 18 4%
Geographic region
Midwest 23 12% 88 16% 79 18% NS
Northeast 29 16% 67 13% 75 17%
South 40 22% 98 18% 75 17%
West 94 51% 282 53% 212 48%
Urban/rural
Metropolitan 165 89% 491 92% 400 91% NS
Nonmetropolitan 21 11% 44 8% 41 9%
Income quartile
Lowest quartile 38 20% 116 22% 91 21% NS
Second quartile 41 22% 149 28% 122 28%
Third quartile 49 26% 118 22% 86 20%
Fourth quartile 58 31% 152 28% 142 32%
Stage
I/II 146 78% 417 78% 318 72% .0687
III/IV 40 22% 118 22% 123 28%
Extranodal extension
Yes 14 8% 64 12% 51 12% NS
No 172 92% 471 88% 390 88%
B symptoms
Absent 146 78% 341 64% 278 63% <.001
Present 8 4% 70 13% 53 12%
Unknown 32 17% 124 23% 110 25%
Radiation
Received 65 35% 296 55% 203 46% <.0001
Did not receive 121 65% 239 45% 238 54%
Diagnosis year
1988-1994 12 6% 57 11% 44 10% NS
1995-2010 174 94% 478 89% 397 90%
Abbreviation: NS Z not significant.
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tion. This lack of difference may be due to the smaller
number of NLPHL patients for any given stage.
In this analysis of more than 30,000 patients, NLPHL
patients had better OS and DSS than CHL patients. In MVA
accounting for other known prognostic features such as
stage at presentation, NLPHL histology was associated
with better OS and DSS. Our finding of improved prognosis
in NLPHL patients after controlling for stage and other
prognostic features is confirmed in the recently published
series using the SEER data (10).
Our findings support previously published reports that
NLPHL patients have more favorable characteristics and
earlier stage at presentation than CHL patients (2, 11).
One novel contribution of the current series is that thisdifference was most pronounced among NLPHL patients
<20 years old who, as compared to older patients with
NLPHL, had a lower incidence of B symptoms and
extranodal extension. Even after controlling for the more
favorable prognostic factors among pediatric patients, age
<20 years old was associated with better OS and DSS
in NLPHL patients. The association of age with outcome
was linear with patients 20 to 45 years of age demon-
strating improved prognosis compared to patients
>45 years old. The more favorable presentation and out-
comes of pediatric NLPHL patients is concordant with
the data for all HL patients in which pediatric patients
present with more favorable disease characteristics and
demonstrate better survival (8). Based on data from the
British Columbia Cancer Agency in which adolescents
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Fig. 2. Use of radiation in early stage nodular
lymphocyte-predominant Hodgkin lymphoma.
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with HL demonstrated similar outcomes (12), it is likely
that the improved prognosis in the patients <20 years old
in this series was driven by the youngest patients, although
the fact that young adults (20-45 years of age) demon-
strated improved prognosis compared to the older adults in
this series provides evidence that age may function as a
continuous variable with older age associated with poorer
outcomes in NLPHL.
Radiation is instrumental in the cure of early stage
NLPHL patients. Radiation alone is the recommended
treatment for patients with stage IA or IIA disease (13).
Large cooperative group trials and single-institution series
demonstrate excellent outcomes from radiation alone in
early stage NLPHL (14-16) or radiation in combination with
chemotherapy (17-19). Recent data from the GHSG dem-
onstrate excellent outcomes with involved-field RT (IFRT)
alone in stage IA patients and show no benefit with the
addition of chemotherapy in early stage patients (20). In this
study, receipt of radiation was associated with better OS and
DSS on MVA with a HR of 0.66 for OS and 0.45 for DSS.
Yet, this study also demonstrated a decline in receipt of
radiation over time, a trend which mirrors the declining use
of radiation in CHL (9). The declining use of radiation may0
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Fig. 3. Use of radiation by year in all nodular
lymphocyte-predominant Hodgkin lymphoma (NLPHL)
patients and those with early stage disease.stem in large part from concern for late effects as data
concerning late effects of radiation in HL survivors have
emerged over the past two and a half decades. Nonradiation-
based strategies including surgical resection followed by
observation and observation alone have been investigated,
particularly in the pediatric population (21-23), but many of
these patients develop relapse and observation alone is not
routinely recommended, with the exception of certain pe-
diatric patients (3). In the recent Children’s Oncology Group
protocol for pediatric patients with early-stage HL, patients
are treated with upfront chemotherapy with no further
treatment if a complete response was achieved (Combina-
tion Chemotherapy Followed by Radiation Therapy in
Treating Young Patients With Newly Diagnosed Hodgkin’s
Lymphoma; clinicaltrials.gov/NCT00302003). These
differing treatment paradigms in the pediatric population as
well as the concern for late effects likely explains our
finding of decreased radiation utilization among patients
<20 years old. Given the expression of CD20 in NLPHL,
prospective studies have also investigated rituximab alone in
early stage disease but despite high response rates, the
relapse rate with rituximab alone is high and thus rituximab
is not routinely used in early-stage disease (24-26).
Although no definitive conclusions can be drawn regarding
the causal association of better OS and DSS with receipt of
radiation, the finding is noteworthy and the downward trend
in radiation utilization is significant in light of this finding.
Despite this downward trend in utilization, radiation tech-
niques have improved and modern techniques such as
involved site RT should be utilized in all patients with LPHL
receiving RT to minimize treatment fields and treatment
morbidity (27).
This study has several limitations owing in large part to
relevant prognostic and treatment data not available in the
SEER database such as ESR, bulky disease, the involve-
ment of three or more nodal regions, the use of chemo-
therapy, and information on relapse. Given these
limitations, this study is unable to answer important
questions with regard to NLPHL in comparison to CHL
such as time-course and rates of relapse, and the use of
chemotherapy and/or rituximab and its association with OS
and DSS. It also introduces potential confounders associ-
ated with histology that cannot be accounted for in the
analysis. An additional weakness of this study is that we
were unable to confirm the cases classified as NLPHL with
central pathology review which, given prior studies
showing high rates of misclassification of NLPHL (1, 28),
likely led to erroneous classification of some of our
patients.Conclusions
Taken together, this large population-based series demon-
strates that better survival of NLPHL patients as compared
to CHL patients persists even after controlling for more
favorable presenting characteristics. It demonstrates an
Table 3 Multivariate analysis of factors associated with overall and disease-specific survival in nodular lymphocyte-predominant
Hodgkin lymphoma patients
Factor
Overall survival Disease-specific survival
HR, 95% CI P HR, 95% CI P
Age
>45 Ref Ref
20-45 0.26 (0.18-0.37) <.0001 0.31 (0.18-0.52) <.0001
<20 0.09 (0.03-0.25) 0.06 (0.01-0.41)
Sex
Female Ref Ref
Male 0.88 (0.62-1.24) NS 0.89 (0.53-1.51) NS
Race
White Ref Ref
Black and other 1.28 (0.87-1.88) NS 1.28 (0.73-2.24) NS
Geographic region
Northeast Ref Ref
Midwest 0.91 (0.48-1.75) NS 1.03 (0.43-2.45) NS
South 0.84 (0.42-1.70) 0.60 (0.21-1.71)
West 1.34 (0.77-2.33) 1.10 (0.52-2.34)
Urban/rural
Metropolitan Ref Ref
Nonmetropolitan 1.03 (0.60-1.78) NS 1.03 (0.43-2.48) NS
Income quartile
Lowest quartile Ref Ref
Second quartile 0.85 (0.56-1.30) NS 1.21 (0.64-2.31) NS
Third quartile 0.67 (0.39-1.14) 0.62 (0.27-1.45)
Fourth quartile 0.92 (0.54-1.57) 1.11 (0.49-2.47)
Stage
III and IV Ref Ref
I and II 0.61 (0.41-0.91) .02 0.47 (0.27-0.82) .01
Extranodal extension
No Ref Ref
Yes 1.43 (0.90-2.27) NS 1.28 (0.66-2.47) NS
B symptoms
Absent Ref Ref
Present 1.23 (0.75-2.02) NS 1.66 (0.84-3.29) NS
Unknown 1.15 (0.79-1.68) 1.62 (0.93-2.83)
Radiation
Did not receive Ref Ref
Received 0.64 (0.44-0.93) .03 0.43 (0.24-0.78) .01
Diagnosis year
1995-2010 Ref Ref
1988-1994 1.69 (1.08-2.63) .02 1.75 (0.87-3.53) NS
Abbreviations: CI Z confidence interval; HR Z hazard ratio; NS Z not significant; Ref Z reference value.
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NLPHL patients while confirming a decline in radiation
utilization for patients with this disease. Further research
refining unique treatment strategies in both early and
advanced NLPHL patients is needed.References
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